White Pine Capital LLC Contrafect Corp Transaction History

White Pine Capital LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$2.79 - $4.45 $106,597 - $170,021	38,207 Added 10.73%	394,424 $1.21 Million
Q1 2022 May 12, 2022	BUY	$2.26 - $3.84 $107,020 - $181,839	47,354 Added 15.33%	356,217 $1.3 Million
Q4 2021 Feb 11, 2022	SELL	$2.47 - $4.14 $141,572 - $237,292	-57,317 Reduced 15.65%	308,863 $812,000
Q3 2021 Nov 10, 2021	BUY	$3.19 - $4.43 $1,059 - $1,470	332 Added 0.09%	366,180 $1.48 Million
Q2 2021 Aug 12, 2021	BUY	$3.58 - $4.9 $579,562 - $793,256	161,889 Added 79.37%	365,848 $1.51 Million
Q1 2021 May 12, 2021	BUY	$4.46 - $6.68 $257,029 - $384,968	57,630 Added 39.38%	203,959 $979,000
Q4 2020 Feb 16, 2021	SELL	$5.05 - $6.4 $78,830 - $99,904	-15,610 Reduced 9.64%	146,329 $739,000
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $53,530 - $74,094	10,600 Added 7.0%	161,939 $855,000
Q2 2020 Aug 12, 2020	BUY	$4.69 - $7.81 $22,558 - $37,566	4,810 Added 3.28%	151,339 $967,000
Q1 2020 May 13, 2020	SELL	$5.5 - $12.3 $7.4 Million - $16.5 Million	-1,344,846 Reduced 90.17%	146,529 $844,000
Q4 2019 Feb 12, 2020	BUY	$2.9 - $6.58 $4.32 Million - $9.81 Million	1,491,375 New	1,491,375 $926,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of White Pine Capital LLC, based on Form 13F filings with the SEC.

Stay updated on White Pine Capital LLC with notifications on news.